![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
Par Pharmaceutical, Inc. SFBC Ft. Myers, Inc |
---|---|
Information provided by: | Par Pharmaceutical, Inc. |
ClinicalTrials.gov Identifier: | NCT00653393 |
To compare the single-dose Bioavailability of Tranylcypromine and Parnate
Condition | Intervention | Phase |
---|---|---|
To Determine the Bioavailability of Tranylcypromine |
Drug: Tranylcypromine Drug: Parnate |
Phase I |
Study Type: | Interventional |
Study Design: | Randomized, Open Label, Crossover Assignment |
Official Title: | To Compare Bioavailability of Kali Tranylcypromine 10mg Tablets to That of Parnate 10 mg Tablets Under Fasting Conditions. |
Enrollment: | 39 |
Study Start Date: | October 2004 |
Study Completion Date: | December 2004 |
Primary Completion Date: | November 2004 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Experimental
Subjects received Kali product under fasting conditions
|
Drug: Tranylcypromine
Tablets, 10 mg, single-dose
|
B: Active Comparator
Subjects received Parnate product under fasting conditions
|
Drug: Parnate
Tablets, 10 mg, single-dose
|
To compare the relative Bioavailability of Tranylcypromine 10 mg tablets with that of PARNATE 10mg tablets in normal,healthy, men and women under fasting conditions
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Florida | |
SFBC Ft. Myers, Inc | |
Ft. Myers, Florida, United States, 33901 |
Principal Investigator: | Antonio Pizzaro | SFBC Ft. Myers, Inc |
Responsible Party: | Par Pharmaceutical, Inc. ( Dr. Alfred Elvin/ Director Biopharmaceutics ) |
Study ID Numbers: | 04-0413-001 |
Study First Received: | April 1, 2008 |
Last Updated: | April 3, 2008 |
ClinicalTrials.gov Identifier: | NCT00653393 |
Health Authority: | United States: Food and Drug Administration |
bioequivalence, single- dose, fasting |
Tranylcypromine |
Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Therapeutic Uses Physiological Effects of Drugs Psychotropic Drugs Monoamine Oxidase Inhibitors |
Central Nervous System Depressants Anti-Anxiety Agents Enzyme Inhibitors Central Nervous System Agents Antidepressive Agents Pharmacologic Actions |